Just a friendly reminder amongst all the noise - the drug itself is a savior, in so many ways, in so many indications, and alongside so many other drugs - the path to proving it is taking longer than initially hoped, but the company is headed in the right direction to actually make this thing happen.

Forecast what you think the eventual annual revenue for this drug can be once the first approval is achieved (because that's when the floodgates open to valuation here given the other indications), add the typical pharma multiple to it, factor in shares outstanding, and you have quite a handsome reward, especially from these levels, if your timeframe & diamond hands allow for it.